https://allsci.com/news/regulatory/ap301-hyperphosphatemia-dialysis-chinas-nmpa/ AllScien 2026-08-07T16:31:47.404147Z China accepts NDA for Alebund's phosphate binder AP301 after Phase III success https://allsci.com/news/regulatory/fda-fast-track-ovarian-cancer-bioinvent-secures/ AllScien 2026-08-07T16:28:01.316068Z BioInvent wins FDA Fast Track for BI-1808 after encouraging ovarian cancer data https://allsci.com/news/first-in-human-trials/triple-agonist-obesity-neurocrine-launches-for/ AllScien 2026-08-07T16:26:00.345852Z Neurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study https://allsci.com/news/approvals/benmelstobart-squamous-lung-cancer-cttqs/ AllScien 2026-08-07T16:21:02.020286Z Sino Bio's benmelstobart-anlotinib regimen adds new China indication in first-line squamous NSCLC https://allsci.com/news/licensing-and-partnerships/arcturus-csl-seqirus-settlement-unwinds-usd-43/ AllScien 2026-08-07T16:13:37.918464Z Arcturus and CSL Seqirus terminate sa-mRNA vaccine partnership https://allsci.com/news/clinical-trials/bmn-401-discontinued-biomarin-discontinues-after/ AllScien 2026-08-07T16:01:43.595151Z BioMarin drops BMN 401 following unsuccessful pivotal trial https://allsci.com/news/licensing-and-partnerships/rna-editing-rett-syndrome-shape-and-research/ AllScien 2026-08-07T15:03:13.253864Z Shape and Rett Syndrome Research Trust advance AI-designed RNA editor for R168X mutation https://allsci.com/news/pipe-financing/tarsus-alkeus-acquisition-funding-secures-usd/ AllScien 2026-08-07T14:59:09.756698Z Tarsus secures USD 125m to fund Alkeus acquisition and expand eye care pipeline https://allsci.com/news/first-in-human-trials/disp-10-immunotherapy-trial-dispatch-bio-launches/ AllScien 2026-08-07T14:50:34.925834Z Dispatch advances synthetic-antigen CAR T platform into first-in-human testing https://allsci.com/news/clinical-trials/fasedienol-social-anxiety-shows-numerical/ AllScien 2026-08-07T14:39:45.790307Z Vistagen reports exploratory Phase II miss for social anxiety drug candidate https://allsci.com/news/clinical-trials/gb268-breast-cancer-trial-edding-genor-initiates/ AllScien 2026-08-07T14:00:52.491081Z Edding Genor tries trispecific PD-1/CTLA-4/VEGF antibody against breast cancer https://allsci.com/news/licensing-and-partnerships/cystic-fibrosis-gene-editing-recode-expands-push/ AllScien 2026-08-07T13:54:55.261650Z ReCode expands cystic fibrosis gene editing push with new CF Foundation backing and unnamed partner https://allsci.com/news/corporate-strategy/biogen-raythera-acquisition-expands-immunology/ AllScien 2026-08-07T13:52:15.337477Z Biogen closes deal for USD 1b buyout of RayThera https://allsci.com/news/regulatory/imvanex-vaccine-children-approval-european/ AllScien 2026-08-07T13:40:45.703745Z EU clears label expansion for Bavarian Nordic's Mpox vaccine to children as young as two https://allsci.com/news/approvals/oncolytic-virus-melanoma-fda-approval-approves/ AllScien 2026-08-07T13:34:42.296798Z Replimune secures accelerated approval for oncolytic viral therapy Tudriqev https://allsci.com/news/ipo-public-listing/latigo-ipo-nav18-raises-usd-3456m-in-upsized/ AllScien 2026-08-07T13:30:11.851572Z Latigo raises USD 345.6m in upsized IPO backed by Nav1.8 Phase II data https://allsci.com/news/corporate-strategy/transcenta-cdmo-assets-sale-exits-manufacturing/ AllScien 2026-08-07T13:23:56.344602Z Transcenta sells CDMO assets to WuXi Bio to focus on drug pipeline https://allsci.com/news/grants/alzheimers-disease-immune-cells-research/ AllScien 2026-08-07T13:11:02.337200Z Washington University wins NIA grant to study immune clearance in Alzheimer's disease https://allsci.com/news/car-phagocyte-pediatric-brain-cancer-university/ AllScien 2026-08-07T12:54:26.474330Z University of Colorado renews work on CAR-phagocyte pediatric brain cancer therapy https://allsci.com/news/research/rna-vaccine-pandemic-niaid-awards-albert-einstein/ AllScien 2026-08-07T12:34:07.687906Z Albert Einstein to optimize RNA vaccine designs for pandemics with NIAID support https://allsci.com/news/research/cd4-t-cell-profiling-platform-university-arizona/ AllScien 2026-08-07T12:26:22.286807Z University of Arizona gets NIAID backing for CD4+ T cell profiling platform https://allsci.com/news/licensing-and-partnerships/s-oxprenolol-actimed-regains-full-control-of/ AllScien 2026-08-06T16:48:50.863280Z Actimed regains full control of S-oxprenolol after five-year partnership with Faraday https://allsci.com/news/approvals/yochanra-cholangiocarcinoma-approval-nmpa/ AllScien 2026-08-06T16:41:13.014244Z TransThera wins first China approval in post-FGFR cholangiocarcinoma https://allsci.com/news/funding/ensysce-cy-biopharma-acquisition-expands-into/ AllScien 2026-08-06T16:36:26.748538Z Ensysce expands into neuroplastogenic pain with USD 77m Cy Biopharma acquisition https://allsci.com/news/pharma/tarsus-alkeus-acquisition-gildeuretinol/ AllScien 2026-08-06T16:30:44.882008Z Tarsus builds retina franchise in USD 800 million Alkeus deal https://allsci.com/news/clinical-trials/anti-fibrotic-antibody-phase-ii-mediar-advances/ AllScien 2026-08-06T16:25:44.514713Z Mediar partners with Ono Pharma on fibro-inflammatory discovery https://allsci.com/news/clinical-trials/bezisterim-parkinsons-trial-meets-motor-and/ AllScien 2026-08-06T16:12:09.652869Z Bezisterim meets motor and non-motor endpoints in phase II early Parkinson's trial. https://allsci.com/news/licensing-and-partnerships/companion-diagnostics-astrazeneca-sophia-genetics/ AllScien 2026-08-06T13:57:38.491902Z Sophia Genetics expands AstraZeneca partnership with two cDX programs https://allsci.com/news/clinical-trials/tardive-dyskinesia-drug-ly03015-luye-pharma/ AllScien 2026-08-06T13:51:07.196810Z Luye clears US bridging milestone for first dual-mechanism TD therapy https://allsci.com/news/hengrui-bravehearts-cardiac-myosin-inhibitor-shows-stronng-early-efficacy-against-cardiomyopathy/ AllScien 2026-08-06T13:16:28.649246Z Hengrui, Braveheart's cardiac myosin inhibitor shows strong early efficacy against cardiomyopathy https://allsci.com/news/licensing-and-partnerships/ai-drug-discovery-bristol-myers-squibb-deploys/ AllScien 2026-08-06T12:44:35.158798Z BMS deploys Schrödinger's agentic AI platform across drug discovery https://allsci.com/news/ipo-public-listing/braveheart-bio-ipo-raises-usd-3825m-in-upsized-to/ AllScien 2026-08-06T12:37:26.326736Z Braveheart Bio ups IPO pricing for USD 382.5m take-home https://allsci.com/news/regulatory-pathways/retatrutide-litigation-classification-lillys/ AllScien 2026-08-06T11:50:52.522531Z Eli Lilly Q2'26: Retatrutide heads toward filing amid BLA dispute https://allsci.com/news/clinical-trials/ziltivekimab-zeus-failure-ziltivekimabs/ AllScien 2026-08-06T11:38:14.986095Z Novo Nordisk Q2'26: ZEUS failure overshadows obesity pipeline advances https://allsci.com/news/clinical-trials/ivonescimab-bladder-cancer-summits-challenges/ AllScien 2026-08-06T09:59:29.961515Z Summit expands ivonescimab's challenge to Keytruda into bladder cancer https://allsci.com/news/approvals/orzeyful-narcolepsy-fda-approval-approves-takedas/ AllScien 2026-08-06T09:28:45.009517Z Takeda ushers in the orexin era with landmark FDA approval https://allsci.com/news/regulatory/lx2020-rmat-designation-fda-grants-lexeos/ AllScien 2026-08-06T09:07:22.984757Z Lexeo's PKP2 cardiomyopathy gene therapy adds RMAT status https://allsci.com/news/approvals/mrna-influenza-vaccine-fda-approves-modernas/ AllScien 2026-08-06T08:57:48.130623Z Moderna's mFlusiva becomes first mRNA influenza vaccine in US https://allsci.com/news/licensing-and-partnerships/angelman-syndrome-gene-therapy-fast-secures/ AllScien 2026-08-06T08:01:27.819524Z FAST taps Apertura's BBB-crossing AAV platform to advance Angelman gene therapy https://allsci.com/news/licensing-and-partnerships/eton-asn-001-hemangioma-acquisition-expands/ AllScien 2026-08-06T07:58:08.636762Z Eton taps China's Auson gel timolol for infantial hemangiomas